SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited (SMSPHARMA.BO) Stock Competitors & Peer Comparison
See (SMSPHARMA.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMSPHARMA.BO | ₹390.80 | +0.53% | 36.5B | 38.86 | ₹10.03 | +0.10% |
| CIPLA.BO | ₹1,202.25 | +0.74% | 970.2B | 21.37 | ₹56.20 | +1.33% |
| CIPLA.NS | ₹1,202.40 | +0.84% | 970.1B | 21.34 | ₹56.28 | +1.33% |
| ABBOTINDIA.BO | ₹25,662.00 | -2.33% | 550.6B | 36.47 | ₹710.49 | +1.83% |
| ABBOTINDIA.NS | ₹25,665.00 | -2.36% | 550.3B | 36.09 | ₹717.58 | +1.83% |
| GLAXO.BO | ₹2,331.20 | +0.90% | 397.5B | 41.68 | ₹56.30 | +2.30% |
| GLAXO.NS | ₹2,333.40 | +0.95% | 397.5B | 38.90 | ₹60.33 | +2.30% |
| GLAND.BO | ₹1,713.95 | +1.42% | 280.2B | 33.10 | ₹51.37 | +1.06% |
| GLAND.NS | ₹1,716.40 | +1.65% | 280.1B | 33.01 | ₹51.50 | +1.06% |
| PFIZER.NS | ₹4,779.20 | -2.21% | 221.4B | 25.92 | ₹186.69 | +3.41% |
Stock Comparison
SMSPHARMA.BO vs CIPLA.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, CIPLA.BO has a market cap of 970.2B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while CIPLA.BO trades at ₹1,202.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas CIPLA.BO's P/E ratio is 21.37. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to CIPLA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check CIPLA.BO's competition here
SMSPHARMA.BO vs CIPLA.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, CIPLA.NS has a market cap of 970.1B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while CIPLA.NS trades at ₹1,202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas CIPLA.NS's P/E ratio is 21.34. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to CIPLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check CIPLA.NS's competition here
SMSPHARMA.BO vs ABBOTINDIA.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, ABBOTINDIA.BO has a market cap of 550.6B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while ABBOTINDIA.BO trades at ₹25,662.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas ABBOTINDIA.BO's P/E ratio is 36.47. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to ABBOTINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check ABBOTINDIA.BO's competition here
SMSPHARMA.BO vs ABBOTINDIA.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, ABBOTINDIA.NS has a market cap of 550.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while ABBOTINDIA.NS trades at ₹25,665.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas ABBOTINDIA.NS's P/E ratio is 36.09. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to ABBOTINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check ABBOTINDIA.NS's competition here
SMSPHARMA.BO vs GLAXO.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, GLAXO.BO has a market cap of 397.5B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while GLAXO.BO trades at ₹2,331.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas GLAXO.BO's P/E ratio is 41.68. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAXO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAXO.BO's competition here
SMSPHARMA.BO vs GLAXO.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, GLAXO.NS has a market cap of 397.5B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while GLAXO.NS trades at ₹2,333.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas GLAXO.NS's P/E ratio is 38.90. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAXO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAXO.NS's competition here
SMSPHARMA.BO vs GLAND.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, GLAND.BO has a market cap of 280.2B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while GLAND.BO trades at ₹1,713.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas GLAND.BO's P/E ratio is 33.10. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAND.BO's competition here
SMSPHARMA.BO vs GLAND.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, GLAND.NS has a market cap of 280.1B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while GLAND.NS trades at ₹1,716.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas GLAND.NS's P/E ratio is 33.01. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAND.NS's competition here
SMSPHARMA.BO vs PFIZER.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, PFIZER.NS has a market cap of 221.4B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while PFIZER.NS trades at ₹4,779.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas PFIZER.NS's P/E ratio is 25.92. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to PFIZER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check PFIZER.NS's competition here
SMSPHARMA.BO vs PFIZER.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, PFIZER.BO has a market cap of 221.4B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while PFIZER.BO trades at ₹4,775.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas PFIZER.BO's P/E ratio is 26.40. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to PFIZER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check PFIZER.BO's competition here
SMSPHARMA.BO vs SANOFICONR.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, SANOFICONR.NS has a market cap of 106.9B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while SANOFICONR.NS trades at ₹4,530.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas SANOFICONR.NS's P/E ratio is 44.46. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SANOFICONR.NS's ROE of +0.79%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to SANOFICONR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SANOFICONR.NS's competition here
SMSPHARMA.BO vs SANOFI.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, SANOFI.BO has a market cap of 77.1B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while SANOFI.BO trades at ₹3,373.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas SANOFI.BO's P/E ratio is 23.64. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SANOFI.BO's ROE of +0.37%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to SANOFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SANOFI.BO's competition here
SMSPHARMA.BO vs SANOFI.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, SANOFI.NS has a market cap of 76.9B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while SANOFI.NS trades at ₹3,381.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas SANOFI.NS's P/E ratio is 23.57. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SANOFI.NS's ROE of +0.37%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to SANOFI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SANOFI.NS's competition here
SMSPHARMA.BO vs MARKSANS.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, MARKSANS.BO has a market cap of 75.4B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while MARKSANS.BO trades at ₹170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas MARKSANS.BO's P/E ratio is 21.43. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to MARKSANS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check MARKSANS.BO's competition here
SMSPHARMA.BO vs MARKSANS.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, MARKSANS.NS has a market cap of 75.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while MARKSANS.NS trades at ₹170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas MARKSANS.NS's P/E ratio is 20.91. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to MARKSANS.NS's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to MARKSANS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check MARKSANS.NS's competition here
SMSPHARMA.BO vs SMSPHARMA.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, SMSPHARMA.NS has a market cap of 36.6B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while SMSPHARMA.NS trades at ₹390.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas SMSPHARMA.NS's P/E ratio is 38.98. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SMSPHARMA.NS's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to SMSPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SMSPHARMA.NS's competition here
SMSPHARMA.BO vs SENORES.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, SENORES.NS has a market cap of 35.8B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while SENORES.NS trades at ₹772.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas SENORES.NS's P/E ratio is 30.25. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to SENORES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SENORES.NS's competition here
SMSPHARMA.BO vs NGLFINE.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, NGLFINE.BO has a market cap of 13.8B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while NGLFINE.BO trades at ₹2,211.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas NGLFINE.BO's P/E ratio is 38.87. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to NGLFINE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check NGLFINE.BO's competition here
SMSPHARMA.BO vs NGLFINE.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, NGLFINE.NS has a market cap of 13.7B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while NGLFINE.NS trades at ₹2,211.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas NGLFINE.NS's P/E ratio is 38.91. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to NGLFINE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check NGLFINE.NS's competition here
SMSPHARMA.BO vs TTKHLTCARE.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, TTKHLTCARE.NS has a market cap of 11.1B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while TTKHLTCARE.NS trades at ₹814.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas TTKHLTCARE.NS's P/E ratio is 18.51. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to TTKHLTCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check TTKHLTCARE.NS's competition here
SMSPHARMA.BO vs KOPRAN.NS Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, KOPRAN.NS has a market cap of 6.1B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while KOPRAN.NS trades at ₹134.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas KOPRAN.NS's P/E ratio is 36.69. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to KOPRAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check KOPRAN.NS's competition here
SMSPHARMA.BO vs KOPRAN.BO Comparison April 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 36.5B. In comparison, KOPRAN.BO has a market cap of 6B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹390.80, while KOPRAN.BO trades at ₹134.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.86, whereas KOPRAN.BO's P/E ratio is 36.62. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.BO is less volatile compared to KOPRAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check KOPRAN.BO's competition here